Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Thiogenesis Therapeutics Corp ( (TSE:TTI) ) is now available.
Thiogenesis Therapeutics Corp announced a non-brokered private placement of 2,000,000 common shares at $0.75 each, aiming to raise $1.5 million. The proceeds will support clinical trial expenses for their lead product TTI-0102, which targets mitochondrial disorders, and general working capital. This move is expected to bolster the company’s financial position and advance its clinical programs, potentially enhancing its standing in the biopharmaceutical industry.
More about Thiogenesis Therapeutics Corp
Thiogenesis Therapeutics Corp is a clinical-stage biopharmaceutical company based in San Diego, CA, publicly traded on the TSX Venture Exchange and OTCQX. The company focuses on developing sulfur-containing prodrugs that serve as precursors to thiol-active compounds, aiming to treat serious pediatric diseases with unmet medical needs. Their lead product candidate, TTI-0102, is involved in clinical trials for conditions such as Mitochondrial Encephalopathy Lactic Acidosis and Stroke (MELAS), Leigh syndrome spectrum (LSS), and plans for trials in Rett syndrome and pediatric Metabolic Dysfunction-Associated Steatohepatitis (MASH).
Average Trading Volume: 34,396
Technical Sentiment Signal: Strong Buy
Current Market Cap: C$37.05M
See more insights into TTI stock on TipRanks’ Stock Analysis page.